Improvement in vulvar vestibulitis with montelukast

Neha Kamdar, Laura Fisher, Colin Macneill

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis. STUDY DESIGN: We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treat-ment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies. RESULTS: Subjects treated with montelukast showed an average of 52% in improvement in symptoms as compared to a 15% improvement in the controls (p <0.0001). CONCLUSION: Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.

Original languageEnglish (US)
Pages (from-to)912-916
Number of pages5
JournalThe Journal of reproductive medicine
Volume52
Issue number10
StatePublished - Oct 2007

Fingerprint

montelukast
Vulvar Vestibulitis
Vulvodynia
Leukotrienes
Signs and Symptoms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Kamdar, Neha ; Fisher, Laura ; Macneill, Colin. / Improvement in vulvar vestibulitis with montelukast. In: The Journal of reproductive medicine. 2007 ; Vol. 52, No. 10. pp. 912-916.
@article{c4d64219016d4fdaafba7c8f450bfae6,
title = "Improvement in vulvar vestibulitis with montelukast",
abstract = "OBJECTIVE: To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis. STUDY DESIGN: We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treat-ment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies. RESULTS: Subjects treated with montelukast showed an average of 52{\%} in improvement in symptoms as compared to a 15{\%} improvement in the controls (p <0.0001). CONCLUSION: Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.",
author = "Neha Kamdar and Laura Fisher and Colin Macneill",
year = "2007",
month = "10",
language = "English (US)",
volume = "52",
pages = "912--916",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "10",

}

Improvement in vulvar vestibulitis with montelukast. / Kamdar, Neha; Fisher, Laura; Macneill, Colin.

In: The Journal of reproductive medicine, Vol. 52, No. 10, 10.2007, p. 912-916.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improvement in vulvar vestibulitis with montelukast

AU - Kamdar, Neha

AU - Fisher, Laura

AU - Macneill, Colin

PY - 2007/10

Y1 - 2007/10

N2 - OBJECTIVE: To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis. STUDY DESIGN: We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treat-ment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies. RESULTS: Subjects treated with montelukast showed an average of 52% in improvement in symptoms as compared to a 15% improvement in the controls (p <0.0001). CONCLUSION: Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.

AB - OBJECTIVE: To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis. STUDY DESIGN: We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treat-ment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies. RESULTS: Subjects treated with montelukast showed an average of 52% in improvement in symptoms as compared to a 15% improvement in the controls (p <0.0001). CONCLUSION: Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.

UR - http://www.scopus.com/inward/record.url?scp=38449089412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449089412&partnerID=8YFLogxK

M3 - Article

C2 - 17977165

AN - SCOPUS:38449089412

VL - 52

SP - 912

EP - 916

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 10

ER -